El interés en corto de Primech Holdings da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Primech Holdings. Los datos de interés en corto se actualizan cada dos semanas.

Primech Holdings (NASDAQ:PMEC) Bolsa, Informe de interés en corto

Primech Holdings

Primech Holdings Ltd is a technology-driven facilities services provider in the public and private sectors operating mainly in Singapore. The services offered by the company include Facilities services, Stewarding services, Cleaning services to offices, Cleaning services to homes, and Cleaning Supplies.

Primech Holdings Ltd

Riot Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIOT#NASDAQ">RIOT</a>) has outperformed the market over the past 5 years by 19.27% on an annualized basis producing an average annual return of 33.81%. Currently, Riot Platforms has a market capitalization of $2.19 billion. 
Buying $100 In RIOT: If an investor had bought $100 of RIOT stock 5 years ago, it would be worth $421.51 today based on a price of $7.23 for RIOT at the time of writing.
<h3>Riot Platforms's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727901324_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

RIOT

Here's How Much $100 Invested In Riot Platforms 5 Years Ago Would Be Worth Today

Ecolab (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ECL#NYSE">ECL</a>) has outperformed the market over the past 20 years by 2.39% on an annualized basis producing an average annual return of 10.81%. Currently, Ecolab has a market capitalization of $72.26 billion. 
Buying $100 In ECL: If an investor had bought $100 of ECL stock 20 years ago, it would be worth $781.21 today based on a price of $253.97 for ECL at the time of writing.
<h3>Ecolab's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727901319_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Ecolab 20 Years Ago Would Be Worth Today

President Joe Biden and his administration purchased an additional <a href="https://www.benzinga.com/markets/eurozone/24/10/41146905/geopolitical-risks-may-be-biggest-threat-to-markets-boe-says">6 million barrels of crude oil</a> earlier this week. 
The acquisition is meant to fill the Strategic Petroleum Reserve. The price tag came in at an average price of $68.56 per barrel, according to Patrick De Haan aka <a href="https://x.com/GasBuddyGuy/status/1840864888291242330">@GasBuddyGuy on X.</a> 
This is just the latest move in a series of oil trades executed by Biden's administration to stabilize the market.
Read Also: <a href="https://www.benzinga.com/trading-ideas/24/10/41144492/brent-crude-oil-prices-rise-amid-geopolitical-tensions">Brent Crude Oil Prices Rise Amid Geopolitical Tensions</a>
The Context: In 2022, Biden ordered the release of more than 100 million barrels of <a href="https://www.benzinga.com/government/24/02/36914512/biden-the-master-oil-trader-part-iii-president-refills-emergency-stash-as-crude-price-slides">oil from the SPR </a>after Russia invaded Ukraine. That created a supply shock in the oil markets. At the time, oil sold for more than $100 per barrel. But, through the release of oil from the SPR, Biden's administration managed to calm the markets, with oil returning to a more normal price of around $80 per barrel. Since then, Biden's team has used periods of weakness in the oil markets to repurchase oil to refill the reserve after releasing a significant amount in 2022.<a href="https://www.benzinga.com/trading-ideas/24/10/41144492/brent-crude-oil-prices-rise-amid-geopolitical-tensions"> </a><a href="https://www.benzinga.com/trading-ideas/24/10/41144492/brent-crude-oil-prices-rise-amid-geopolitical-tensions"> </a>"DOE announces another 6 million barrels of crude oil have been purchased for the SPR, for delivery Feb thru May of 2025," <a href="https://x.com/GasBuddyGuy/status/1840864888291242330">De Haan tweeted Monday.</a> "DOE has now purchased over 55 million barrels to refill the SPR."
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">BREAKING: DOE announces another 6 million barrels of crude oil have been purchased for the SPR, for delivery Feb thru May of 2025. DOE has now purchased over 55 million barrels to refill the SPR.
&mdash; Patrick De Haan &#x26fd;&#xFE0F;&#x1f4ca; (@GasBuddyGuy) <a href="https://twitter.com/GasBuddyGuy/status/1840864888291242330?ref_src=twsrc%5Etfw">September 30, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Quoted: Todd Campbell, the editor-in-chief of TheStreet,<a href="https://x.com/ebcapital/status/1840923025690018087"> responded </a>to De Haan's tweet, saying Biden's move "has to be one of the best oil trades in history." While the administration still has not fully refilled the SPR to its pre-Russia invasion levels, the trades showcase how governments may intervene to help stabilize markets in times of uncertainty. When Biden originally released millions of barrels of oil from the SPR, gas prices were skyrocketing, putting pressure on American consumers. The release from the SPR led to a 40-cent-per-gallon decrease in gas prices, according to the Department of Energy. Now, as gas prices have returned to relatively normal levels, the administration's focus has shifted to refilling the SPR. On Wednesday, the United States Oil Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USO#NYSE">USO</a>), a fund that roughly tracks the price of oil, fell by more than 2% intraday amid ongoing unrest and uncertainty in the Middle East. The Energy Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) also fell early in the trading day, but erased some of those losses and was in the green as of late in Wednesday's session. Keep Reading: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41143156/oil-prices-spike-energy-stocks-jump-after-irans-missile-attack-on-israel-what-investors-need-to-know">Oil Prices Spike, Energy Stocks Jump After Iran&#8217;s Missile Attack On Israel: What Investors Need To Know</a></li>
</ul>
Image: Shutterstock

Commodities

Politics

Markets

General

Biden The Master Oil Trader Part IV? President Loads Up On Millions Of Barrels To Refill Emergency Stash In 'One Of The Best Oil Trades In History'

<ul>
<li>Maximum USD 100 million to purchase up to an aggregate of 10,000,000 of the Company's common shares, with 1,507,328 shares repurchased for USD 11,629,758 as of the date hereof. &nbsp;</li>
<li>A period from and including 5 October 2024 to and including 4 October 2025.
<ul>
<li>The share buy-backs will be carried out by way of repurchases in the market, both on the Oslo Stock Exchange and on Nasdaq.</li>
</ul>
</li>
</ul>

Buybacks

GOGL

Golden Ocean Group Extends Existing Buy-Back Program With 12 Months

Maryland American Water Receives Commission Approval For Acquisition Of Severn Water Company For ~$1.6M

Levi Strauss &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEVI#NYSE">LEVI</a>) shares are trading lower following the company&#8217;s third-quarter financial results released after Wednesday&#8217;s closing bell. Here's a look at the <a href="https://www.benzinga.com/pressreleases/24/10/b41150661/levi-strauss-co-reports-third-quarter-2024-financial-results">details from the report. </a>
The Details: Levi Strauss reported quarterly earnings of 33 cents per share, which beat the analyst consensus estimate of 31 cents. Quarterly revenue came in at $1.516 billion, which missed the analyst consensus estimate of $1.55 billion.
<ul>
<li>DTC (Direct-to-Consumer) net revenues increased 10% on a reported basis and 12% on a constant-currency basis. DTC growth reflected a 12% increase in the U.S. and a 9% increase in Europe.</li>
<li>Wholesale net revenues decreased 6% on a reported basis and 5% on a constant-currency basis. Adjusting for the exit of the Denizen business, wholesale net revenues declined 3%.</li>
<li>Operating margin was 2.0% compared to 2.3% in the same quarter last year inclusive of an impairment charge of $111 million related to the Beyond Yoga acquisition.</li>
<li>Gross margin increased 440 basis points to 60% from 55.6% in the same quarter last year primarily driven by lower product costs and favorable channel and brand mix.</li>
</ul>
Read Next: <a href="https://www.benzinga.com/news/24/10/41129365/what-happened-with-rivian-stock-today">What Happened With Rivian Stock Today?</a>
&#8220;The underlying fundamentals of our business are getting stronger, driven by the Levi&#8217;s&#xAE; brand, which grew 5% globally in Q3, a significant acceleration from H1 and the highest revenue growth in two years. We are making progress against our strategic priorities, including double-digit growth in our direct-to-consumer business, continued positive performance in the U.S., and Europe inflecting to growth,&#8221; said Michelle Gass, CEO of Levi Strauss &amp; Co.
Outlook: Levi Strauss sees fiscal year 2024 adjusted earnings at a mid-point of between $1.17 and $1.27 per share, versus the $1.25 estimate. 
LEVI Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Levi Strauss shares are down 6.22% after-hours at $19.75 after dropping 2.86% in Wednesday&#8217;s regular trading session.
Read Also:
<ul>
<li><a href="https://www.benzinga.com/news/24/09/41104861/elon-musk-tesla-win-dismissal-of-full-self-driving-claims-judge-tosses-lawsuit">Elon Musk, Tesla Win Dismissal Of Full-Self Driving Claims: Judge Tosses Lawsuit</a></li>
</ul>
Photo: Courtesy of Levi Strauss &amp; Co.

Earnings

After-Hours Center

Movers

LEVI

Levi Strauss & Co Stock Falls After Mixed Q3 Results: EPS Beat, Revenues Miss

The Lydian Includes 129 Homes And 23K Sq Ft Of Office/Retail Space; Acquisition Financed Through $35M Mortgage Debt, $14.5M In Operating Partnership Units, And Cash

Centerspace Expands Denver Presence With $54M Acquisition Of The Lydian; Completes Redemption Of 6.625% Series C Preferred Shares; YTD ATM Sales Of 1.59M Shares With $113.73M In Gross Proceeds Used For Preferred Share Redemption And Debt Pay Down

Whales with a lot of money to spend have taken a noticeably bearish stance on Zscaler.
Looking at options history for Zscaler (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZS#NASDAQ">ZS</a>) we detected 9 trades.
If we consider the specifics of each trade, it is accurate to state that 22% of the investors opened trades with bullish expectations and 55% with bearish.
From the overall spotted trades, 2 are puts, for a total amount of $365,000 and 7, calls, for a total amount of $1,123,045.
<h3>Projected Price Targets</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $135.0 to $230.0 for Zscaler over the recent three months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Zscaler's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Zscaler's substantial trades, within a strike price spectrum from $135.0 to $230.0 over the preceding 30 days.
<h3>Zscaler 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727901137_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ZS</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$11.6</td>
<td>$10.85</td>
<td>$11.25</td>
<td>$180.00</td>
<td>$675.0K</td>
<td>820</td>
<td style="text-align: right;">600</td>
</tr>
<tr>
<td>ZS</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>09/19/25</td>
<td>$11.3</td>
<td>$10.65</td>
<td>$11.0</td>
<td>$135.00</td>
<td>$275.0K</td>
<td>18</td>
<td style="text-align: right;">250</td>
</tr>
<tr>
<td>ZS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$40.7</td>
<td>$40.55</td>
<td>$40.55</td>
<td>$145.00</td>
<td>$93.2K</td>
<td>108</td>
<td style="text-align: right;">23</td>
</tr>
<tr>
<td>ZS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$8.1</td>
<td>$7.5</td>
<td>$7.5</td>
<td>$175.00</td>
<td>$90.0K</td>
<td>253</td>
<td style="text-align: right;">120</td>
</tr>
<tr>
<td>ZS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$38.0</td>
<td>$37.3</td>
<td>$37.3</td>
<td>$150.00</td>
<td>$89.5K</td>
<td>2.6K</td>
<td style="text-align: right;">95</td>
</tr>
</tbody>
</table>

<h3>About Zscaler</h3>
Zscaler is a software-as-a-service, or SaaS, firm focusing on providing cloud-native cybersecurity solutions to primarily enterprise customers. Zscaler's offerings can be broadly partitioned into Zscaler Internet Access, which provides secure access to external applications, and Zscaler Private Access, which provides secure access to internal applications. The firm is headquartered in San Jose, California, and went public in 2018.
Following our analysis of the options activities associated with Zscaler, we pivot to a closer look at the company's own performance.
<h3>Present Market Standing of Zscaler</h3>
<ul>
<li>With a volume of 1,255,322, the price of ZS is up 1.52% at $169.53. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 54 days.</li>
</ul>
<h3>What Analysts Are Saying About Zscaler</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $206.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from JP Morgan keeps a Overweight rating on Zscaler with a target price of $220. 
&#x2A; An analyst from Barclays has decided to maintain their Overweight rating on Zscaler, which currently sits at a price target of $200. 
&#x2A; Maintaining their stance, an analyst from Needham continues to hold a Strong Buy rating for Zscaler, targeting a price of $235. 
&#x2A; Consistent in their evaluation, an analyst from BTIG keeps a Buy rating on Zscaler with a target price of $205. 
&#x2A; An analyst from Cantor Fitzgerald has decided to maintain their Neutral rating on Zscaler, which currently sits at a price target of $170. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Zscaler, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Decoding Zscaler's Options Activity: What's the Big Picture?

Whales with a lot of money to spend have taken a noticeably bearish stance on Accenture.
Looking at options history for Accenture (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACN#NYSE">ACN</a>) we detected 9 trades.
If we consider the specifics of each trade, it is accurate to state that 22% of the investors opened trades with bullish expectations and 66% with bearish.
From the overall spotted trades, 6 are puts, for a total amount of $260,055 and 3, calls, for a total amount of $120,743.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $320.0 and $380.0 for Accenture, spanning the last three months.
<h3>Volume &amp; Open Interest Development</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Accenture's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Accenture's significant trades, within a strike price range of $320.0 to $380.0, over the past month.
<h3>Accenture Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727901133_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$35.7</td>
<td>$33.8</td>
<td>$35.7</td>
<td>$370.00</td>
<td>$89.2K</td>
<td>62</td>
<td style="text-align: right;">35</td>
</tr>
<tr>
<td>ACN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$15.7</td>
<td>$15.6</td>
<td>$15.6</td>
<td>$360.00</td>
<td>$56.1K</td>
<td>1.0K</td>
<td style="text-align: right;">49</td>
</tr>
<tr>
<td>ACN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$1.5</td>
<td>$1.45</td>
<td>$1.5</td>
<td>$325.00</td>
<td>$47.2K</td>
<td>252</td>
<td style="text-align: right;">331</td>
</tr>
<tr>
<td>ACN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$27.7</td>
<td>$26.8</td>
<td>$27.7</td>
<td>$370.00</td>
<td>$38.7K</td>
<td>57</td>
<td style="text-align: right;">18</td>
</tr>
<tr>
<td>ACN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$35.6</td>
<td>$33.2</td>
<td>$35.6</td>
<td>$370.00</td>
<td>$35.6K</td>
<td>62</td>
<td style="text-align: right;">50</td>
</tr>
</tbody>
</table>

<h3>About Accenture</h3>
Accenture is a leading global IT-services firm that provides consulting, strategy, and technology and operational services. These services run the gamut from aiding enterprises with digital transformation to procurement services to software system integration. The company provides its IT offerings to a variety of sectors, including communications, media and technology, financial services, health and public services, consumer products, and resources. Accenture employs just under 500,000 people throughout 200 cities in 51 countries.
After a thorough review of the options trading surrounding Accenture, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Current Position of Accenture</h3>
<ul>
<li>With a volume of 2,228,852, the price of ACN is up 1.22% at $356.29. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 78 days.</li>
</ul>
<h3>Expert Opinions on Accenture</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $376.6.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from B of A Securities has decided to maintain their Buy rating on Accenture, which currently sits at a price target of $388. 
&#x2A; Consistent in their evaluation, an analyst from JP Morgan keeps a Overweight rating on Accenture with a target price of $376. 
&#x2A; Maintaining their stance, an analyst from Piper Sandler continues to hold a Neutral rating for Accenture, targeting a price of $329. 
&#x2A; Consistent in their evaluation, an analyst from BMO Capital keeps a Market Perform rating on Accenture with a target price of $390. 
&#x2A; Showing optimism, an analyst from TD Cowen upgrades its rating to Buy with a revised price target of $400. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Accenture with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Spotlight on Accenture: Analyzing the Surge in Options Activity

Whales with a lot of money to spend have taken a noticeably bullish stance on Moderna.
Looking at options history for Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) we detected 44 trades.
If we consider the specifics of each trade, it is accurate to state that 63% of the investors opened trades with bullish expectations and 29% with bearish.
From the overall spotted trades, 30 are puts, for a total amount of $2,727,271 and 14, calls, for a total amount of $652,606.
<h3>Projected Price Targets</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $40.0 to $175.0 for Moderna over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for Moderna options trades today is 1078.22 with a total volume of 29,102.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Moderna's big money trades within a strike price range of $40.0 to $175.0 over the last 30 days.
<h3>Moderna Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727901128_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$8.25</td>
<td>$8.0</td>
<td>$8.05</td>
<td>$55.00</td>
<td>$1.0M</td>
<td>1.4K</td>
<td>1.2K</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$22.9</td>
<td>$22.0</td>
<td>$22.4</td>
<td>$75.00</td>
<td>$232.9K</td>
<td>1.3K</td>
<td>104</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$6.15</td>
<td>$5.75</td>
<td>$6.05</td>
<td>$50.00</td>
<td>$229.2K</td>
<td>1.2K</td>
<td>1.0K</td>
</tr>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$8.9</td>
<td>$7.0</td>
<td>$7.0</td>
<td>$95.00</td>
<td>$138.6K</td>
<td>5</td>
<td>198</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$37.4</td>
<td>$37.3</td>
<td>$37.4</td>
<td>$100.00</td>
<td>$127.1K</td>
<td>3.5K</td>
<td>34</td>
</tr>
</tbody>
</table>

<h3>About Moderna</h3>
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
After a thorough review of the options trading surrounding Moderna, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Present Market Standing of Moderna</h3>
<ul>
<li>Trading volume stands at 4,087,379, with MRNA's price down by -1.17%, positioned at $63.18.</li>
<li>RSI indicators show the stock to be may be approaching oversold.</li>
<li>Earnings announcement expected in 29 days.</li>
</ul>
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Moderna with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

MRNA

Moderna Unusual Options Activity For October 02

Management

HTBK

Heritage Commerce Appoints Thomas Sa As COO Of Company And The Bank

<h3>Gainers</h3>
<ul>
<li>Thunder Power Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIEV#NASDAQ">AIEV</a>) stock increased by 15.6% to $0.55 during Wednesday's after-market session. The company's market cap stands at $38.6 million. </li>
<li>Jowell Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JWEL#NASDAQ">JWEL</a>) shares increased by 11.16% to $2.27. The company's market cap stands at $4.9 million. </li>
<li>Kaixin Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KXIN#NASDAQ">KXIN</a>) stock increased by 9.55% to $0.37. The market value of their outstanding shares is at $22.3 million. </li>
<li>AYRO (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AYRO#NASDAQ">AYRO</a>) shares moved upwards by 4.99% to $0.86. The company's market cap stands at $5.9 million. </li>
<li>Lovesac (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOVE#NASDAQ">LOVE</a>) shares increased by 4.98% to $27.57. The market value of their outstanding shares is at $428.9 million. </li>
<li>Yoshitsu Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TKLF#NASDAQ">TKLF</a>) shares moved upwards by 4.91% to $0.58. The market value of their outstanding shares is at $24.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Levi Strauss (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEVI#NYSE">LEVI</a>) shares fell 7.0% to $19.58 during Wednesday's after-market session. The company's market cap stands at $7.7 billion. As per the news, the Q3 earnings report came out today. </li>
<li>E-Home Household Service (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EJH#NASDAQ">EJH</a>) stock decreased by 3.81% to $1.01. The market value of their outstanding shares is at $8.6 million. </li>
<li>Color Star Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADD#NASDAQ">ADD</a>) shares fell 3.81% to $1.01. The market value of their outstanding shares is at $57.0 million. </li>
<li>Genius Gr (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GNS#AMEX">GNS</a>) shares fell 3.73% to $0.9. The market value of their outstanding shares is at $19.5 million. </li>
<li>Life Time Group Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LTH#NYSE">LTH</a>) shares decreased by 3.42% to $23.2. The market value of their outstanding shares is at $4.7 billion. </li>
<li>SRIVARU Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVMH#NASDAQ">SVMH</a>) shares fell 2.44% to $0.08. The company's market cap stands at $2.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AIEV

AYRO

JWEL

KXIN

LOVE

SVMH

TKLF

12 Consumer Discretionary Stocks Moving In Wednesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Carmell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTCX#NASDAQ">CTCX</a>) stock rose 31.0% to $0.46 during Wednesday's after-market session. The company's market cap stands at $9.6 million. </li>
<li>Processa Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCSA#NASDAQ">PCSA</a>) shares rose 30.07% to $1.73. The market value of their outstanding shares is at $5.6 million. </li>
<li>China Pharma Holdings, Inc. Common Stock (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CPHI#AMEX">CPHI</a>) stock rose 8.83% to $0.28. </li>
<li>Eagle Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EGRX#NASDAQ">EGRX</a>) shares increased by 7.94% to $2.31. The market value of their outstanding shares is at $29.9 million. </li>
<li>Bone Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBLG#NASDAQ">BBLG</a>) stock moved upwards by 7.89% to $1.64. The company's market cap stands at $2.9 million. </li>
<li>Conduit Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDT#NASDAQ">CDT</a>) shares increased by 7.36% to $0.1. The market value of their outstanding shares is at $9.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Soligenix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNGX#NASDAQ">SNGX</a>) stock declined by 8.6% to $4.45 during Wednesday's after-market session. The company's market cap stands at $10.1 million. </li>
<li>Inspire Veterinary (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVP#NASDAQ">IVP</a>) shares fell 6.34% to $0.28. The company's market cap stands at $2.1 million. </li>
<li>Kairos Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KAPA#AMEX">KAPA</a>) stock decreased by 5.3% to $1.25. The company's market cap stands at $16.0 million. </li>
<li>Gossamer Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOSS#NASDAQ">GOSS</a>) stock declined by 4.77% to $1.0. The market value of their outstanding shares is at $226.2 million. </li>
<li>Fractyl Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GUTS#NASDAQ">GUTS</a>) shares fell 4.75% to $2.21. The market value of their outstanding shares is at $105.9 million. </li>
<li>TNF Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNFA#NASDAQ">TNFA</a>) shares fell 4.66% to $1.64. The market value of their outstanding shares is at $3.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BBLG

CPHI

CTCX

EGRX

GOSS

GUTS

KAPA

PCSA

SNGX

TNFA

12 Health Care Stocks Moving In Wednesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Graphex Gr (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GRFX#AMEX">GRFX</a>) stock moved upwards by 15.0% to $0.24 during Wednesday's after-market session. The market value of their outstanding shares is at $12.1 million. </li>
<li>Lucas GC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGCL#NASDAQ">LGCL</a>) stock rose 3.96% to $1.05. The company's market cap stands at $83.5 million. </li>
<li>VCI Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCIG#NASDAQ">VCIG</a>) stock increased by 3.94% to $0.14. The market value of their outstanding shares is at $20.4 million. </li>
<li>Hyperscale Data (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GPUS#AMEX">GPUS</a>) shares increased by 3.63% to $0.23. The company's market cap stands at $8.7 million. </li>
<li>AgEagle Aerial Sys (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/UAVS#AMEX">UAVS</a>) shares rose 3.39% to $0.14. The market value of their outstanding shares is at $2.0 million. </li>
<li>Castor Maritime (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTRM#NASDAQ">CTRM</a>) shares moved upwards by 2.93% to $4.43. The market value of their outstanding shares is at $42.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Nixxy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIXX#NASDAQ">NIXX</a>) shares declined by 9.5% to $2.1 during Wednesday's after-market session. The market value of their outstanding shares is at $8.4 million. </li>
<li>Professional Diversity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPDN#NASDAQ">IPDN</a>) stock decreased by 8.81% to $0.67. The market value of their outstanding shares is at $8.5 million. </li>
<li>XCHG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCH#NASDAQ">XCH</a>) shares declined by 8.68% to $13.26. The company's market cap stands at $786.6 million. </li>
<li>Polar Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POLA#NASDAQ">POLA</a>) stock decreased by 5.0% to $0.49. The market value of their outstanding shares is at $8.6 million. </li>
<li>Surf Air Mobility (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SRFM#NYSE">SRFM</a>) stock decreased by 4.77% to $1.6. The market value of their outstanding shares is at $20.5 million. </li>
<li>Singularity Future Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGLY#NASDAQ">SGLY</a>) stock declined by 4.57% to $1.67. The company's market cap stands at $5.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CTRM

GPUS

GRFX

IPDN

LGCL

NIXX

POLA

SGLY

SRFM

UAVS

VCIG

12 Industrials Stocks Moving In Wednesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>AMTD Digital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HKD#NYSE">HKD</a>) shares increased by 33.6% to $5.22 during Wednesday's after-market session. The market value of their outstanding shares is at $1.0 billion. </li>
<li>CCSC Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCTG#NASDAQ">CCTG</a>) stock moved upwards by 11.06% to $1.6. The company's market cap stands at $18.5 million. </li>
<li>Evolv Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVLV#NASDAQ">EVLV</a>) stock rose 7.69% to $4.2. The market value of their outstanding shares is at $661.7 million. </li>
<li>Glimpse Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRAR#NASDAQ">VRAR</a>) stock rose 6.15% to $0.77. The company's market cap stands at $13.9 million. As per the press release, Q4 earnings came out 2 days ago. </li>
<li>Iveda Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVDA#NASDAQ">IVDA</a>) shares moved upwards by 4.34% to $1.68. The market value of their outstanding shares is at $3.7 million. </li>
<li>Yxt.Com Group Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YXT#NASDAQ">YXT</a>) stock moved upwards by 4.0% to $2.6. The market value of their outstanding shares is at $156.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Infobird Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IFBD#NASDAQ">IFBD</a>) shares decreased by 4.2% to $2.06 during Wednesday's after-market session. The market value of their outstanding shares is at $4.0 million. </li>
<li>Ostin Technology Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OST#NASDAQ">OST</a>) shares fell 3.75% to $0.38. The market value of their outstanding shares is at $5.6 million. </li>
<li>MMTEC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTC#NASDAQ">MTC</a>) shares fell 3.54% to $0.74. The company's market cap stands at $147.3 million. </li>
<li>Intchains Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICG#NASDAQ">ICG</a>) shares decreased by 3.02% to $4.5. The company's market cap stands at $270.0 million. </li>
<li>Netgear (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTGR#NASDAQ">NTGR</a>) shares decreased by 2.79% to $19.25. The market value of their outstanding shares is at $559.5 million. </li>
<li>BTCS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTCS#NASDAQ">BTCS</a>) stock declined by 2.59% to $1.13. The company's market cap stands at $18.2 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BTCS

CCTG

EVLV

IFBD

IVDA

NTGR

VRAR

12 Information Technology Stocks Moving In Wednesday's After-Market Session

WIIM

SPRO

Spero Therapeutics shares are trading higher after the company announced the publication of data from its Phase 1 clinical trial, which assessed the intrapulmonary pharmacokinetics of SPR719.

Plans To Increase Valuation And Regain Compliance; Shares Will Continue Trading With ".BC" Designation Indicating Below Compliance Status; No Immediate Impact On Business Operations Or SEC Reporting Requirements

Know Labs Receives NYSE American Noncompliance Notice For Not Meeting Listing Standards

Biotech

Spero Therapeutics Publishes SPR720 Phase 1 Lung Exposure Data In Antimicrobial Agents And Chemotherapy

Ollie&#39;s Bargain Outlet Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/olli#NASDAQ">OLLI</a>) is set to enhance its retail footprint following the acquisition of seven former Big Lots store leases won through a recent bankruptcy auction. This acquisition comes as part of the ongoing restructuring efforts of Big Lots, which included the closure of 143 stores.
<h2>Details of OLLI&#39;s Acquisition of 7 Big Lots&#39; Stores</h2>
Of the seven stores, Ollie&#39;s Bargain has received the final clearance and approval for six stores from the United States Bankruptcy Court for the District of Delaware. The seventh store is expected to receive the necessary approvals soon.
What makes these stores an ideal choice is that these have the required size, situated in prime trade areas and align with OLLI&#39;s commitment to serving value-oriented customers. Not only this but these stores also are located in the Midwest, a region where OLLI sees significant growth potential and has opened a new distribution center.
Similar to the 99 Cent Only stores&#39; acquisition, OLLI&#39;s primary focus is on opening the acquired Big Lots stores while adjusting the schedule for other planned store openings in its pipeline to optimize productivity and reduce pre-opening costs. For fiscal 2024, the company anticipates 50 new stores and two planned closures.
Ollie&#39;s Bargain&#39;s acquisition of former Big Lots stores signifies a strategic growth initiative within the competitive retail landscape. Currently, OLLI operates 541 stores across 31 states. The company&#39;s long-term plan is to operate 1300 stores across the United States.
<h2>What More Should Investors Know About OLLI?</h2>
Ollie&#39;s Bargain business model of &quot;buying cheap and selling cheap&quot;, cost-containment efforts, focus on store productivity and expansion of customer reward program and Ollie&#39;s Army reinforce its position in the industry. Ollie&#39;s Army continues to be a significant sales driver in the second quarter of fiscal 2024 with the increasing membership. The company ended the quarter with 14.5 million active Ollie&#39;s Army members, which accounted for more than 80% of sales. Collectively, these initiatives position the company for sustained growth.
OLLI delivered a strong performance in the second quarter. It emphasizes value-driven merchandise assortments, which allowed the company to seize market opportunities and meet consumer demand effectively. Comparable store sales rose 5.8% in the quarter, driven by growth in transactions and basket size. Ollie&#39;s Bargain has now achieved nine consecutive quarters of comparable store sales growth.
The improved business performance prompted management to lift its fiscal 2024 view. OLLI now expects net sales in the range of $2.276-$2.291 billion compared with $2.257-$2.277 billion stated earlier. Ollie&#39;s Bargain now anticipates comparable store sales to rise in the band of 2.7-3.2% compared with 1.5-2.3% previously stated. The company has revised adjusted EPS to be in the band of $3.22-$3.30, up from the earlier estimated range of $3.18-$3.28.
<h2>How is the Zacks Consensus Estimate Faring for OLLI?</h2>
Reflecting the positive sentiment around OLLI, the Zacks Consensus Estimate for EPS has seen upward revisions. In the past 60 days, analysts have increased their estimates for the current and next fiscal year by 0.3% to $3.28 and 1.1% to $3.72 per share, respectively. These estimates indicate expected year-over-year growth of 12.7% and 13.4%, respectively.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/75/80055.jpg?v=1028948304" />
Image Source: Zacks Investment Research
<h2>Does OLLI Stock Look Attractive?</h2>
In the past six months, OLLI&#39;s shares have gained 38.5%, outpacing the industry and the S&amp;P 500&#39;s growth of 6.8% and 9.9%, respectively.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/da/80057.jpg?v=2118532209" />
Image Source: Zacks Investment Research
OLLI stock has been a strong performer, but its valuation remains a topic of debate. Currently, the stock trades at a premium relative to the industry, with a price-to-earnings ratio indicating that its growth potential may already be factored into price.
OLLI&#39;s forward 12-month price-to-earnings ratio stands at 26.7X, higher than the industry&#39;s ratio of 18.6X. This suggests that investors are paying a premium compared with the company&#39;s expected earnings growth. OLLI has a Value Score of D.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/70/80056.jpg?v=1422364156" />
Image Source: Zacks Investment Research
<h2>How to Play OLLI Stock?</h2>
Ollie&#39;s Bargain is well-positioned to enhance its market presence, drive sales and deliver value to its customers, leading to improved financial performance in the coming quarters. Investors with a long-term horizon may stay invested in this Zacks Rank #3 (Hold) stock but potential investors should look for a better entry point, given its higher valuation.
<h2>Stocks to Consider</h2>
Here, we have highlighted three better-ranked stocks, namely Sprouts Farmers Market, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sfm#NASDAQ">SFM</a>), Burlington Stores, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/burl#NYSE">BURL</a>) and Chewy, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/chwy#NYSE">CHWY</a>), currently carrying a Zacks Rank # 2 (Buy) each.
Sprouts Farmers engages in the retailing of fresh, natural and organic food products under the Sprouts brand in the United States. SFM has a trailing four-quarter earnings surprise of nearly 12%, on average.
The Zacks Consensus Estimate for Sprouts Farmers&#39; current-fiscal year&#39;s sales and earnings indicates growth of 9.6% and 18.7%, respectively, from the year-ago reported numbers.
Burlington Stores operates as a retailer of branded merchandise in the United States. BURL has a trailing four-quarter earnings surprise of 18.4%, on average.
The Zacks Consensus Estimate for Burlington Stores&#39; current-financial year&#39;s sales and earnings implies a rise of 10.1% and 30.5%, respectively, from the year-earlier reported figures.
Chewy engages in the pure-play e-commerce business in the United States. CHWY has a trailing four-quarter earnings surprise of 50.9%, on average.
The Zacks Consensus Estimate for Chewy&#39;s current-financial year&#39;s sales and earnings indicates an increase of 5.7% and 65.2%, respectively, from the year-ago reported numbers.
<a href="https://www.zacks.com/stock/news/2344979/olli-expands-with-7-big-lots-stores-what-more-should-investors-know?cid=CS-BENZ-FT-analyst_blog|company_news_corporate_actions-2344979">To read this article on Zacks.com click here.</a>

Large Cap

Mid Cap

Analyst Ratings

BURL

CHWY

OLLI

OLLI Expands With 7 Big Lots Stores: What More Should Investors Know?

<a href="https://x.com/allyversprille/status/1841574905470386647" title="https://x.com/allyversprille/status/1841574905470386647">https://x.com/allyversprille/status/1841574905470386647</a>

Bloomberg Reporter Post On X, " FAA has concluded its review of United Airlines which followed a spate of safety incidents at the carrier earlier this year. The review didn't identify "any significant safety issues," the regulator said in a statement to Bloomberg.'

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
It&rsquo;s time to start Tuesday with a breakdown of the biggest pre-market stock movers traders will want to know about this morning!



Moving stocks this morning are new agreements and deals, clinical trial data, a bankruptcy filing and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>MicroAlgo (NASDAQ:<a href="https://investorplace.com/stock-quotes/mlgo-stock-quote/">MLGO</a>) stock is rocketing more than 205% after announcing a <a href="https://www.nasdaq.com/press-release/microalgo-inc-nasdaq-mlgo-announced-jointly-establish-micro-consciousness-quantum">joint micro-consciousness quantum research center</a> with WIMI (NASDAQ:<a href="https://investorplace.com/stock-quotes/wimi-stock-quote/">WIMI</a>).</li>



<li>Fresh2 Group (NASDAQ:<a href="https://investorplace.com/stock-quotes/fres-stock-quote/">FRES</a>) shares are soaring over 74% alongside heavy pre-market trading.</li>



<li>Core Scientific (NASDAQ:<a href="https://investorplace.com/stock-quotes/corz-stock-quote/">CORZ</a>) stock is surging more than 48% on an <a href="https://www.businesswire.com/news/home/20240603752657/en/Core-Scientific-to-Provide-Approximately-200-MW-of-Infrastructure-to-Host-CoreWeave%E2%80%99s-High-Performance-Computing-Services-Capturing-Significant-AI-Compute-Opportunity">artificial intelligence (AI) infrastructure deal</a>.</li>



<li>Annexon (NASDAQ:<a href="https://investorplace.com/stock-quotes/annx-stock-quote/">ANNX</a>) shares are increasing over 33% on positive <a href="https://www.nasdaq.com/press-release/annexon-announces-positive-topline-results-pivotal-phase-3-trial-first-class-c1q">Phase 3 clinical trial results</a>.</li>



<li>Plutonian Acquisition (NASDAQ:<a href="https://investorplace.com/stock-quotes/pltn-stock-quote/">PLTN</a>) stock is rising close to 30% without any clear news this morning.</li>



<li>Datasea (NASDAQ:<a href="https://investorplace.com/stock-quotes/dtss-stock-quote/">DTSS</a>) shares are gaining more than 21% on Tuesday morning.</li>



<li>SunLink Health Systems (NYSEMKT:<a href="https://investorplace.com/stock-quotes/ssy-stock-quote/">SSY</a>) stock is climbing over 21% after <a href="https://www.nasdaq.com/press-release/sunlink-health-systems-inc-announces-sale-trace-extended-care-rehab-2024-06-03">selling some of its assets</a>.</li>



<li>Lexaria Bioscience (NASDAQ:<a href="https://investorplace.com/stock-quotes/lexx-stock-quote/">LEXX</a>) shares are heading 18% higher on a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318368667&amp;type=PDF&amp;symbol=LEXX&amp;cdn=3c5f428b59a4d15cb4a8011d5c00dc9b&amp;companyName=Lexaria+Bioscience+Corp.&amp;formType=S-1&amp;formDescription=Registration+statement+under+Securities+Act+of+1933&amp;dateFiled=2024-06-03">secondary stock offering</a>.</li>



<li>FibroGen (NASDAQ:<a href="https://investorplace.com/stock-quotes/fgen-stock-quote/">FGEN</a>) stock is jumping more than 16% on a <a href="https://finance.yahoo.com/news/fibrogen-announces-clinical-trial-supply-200500592.html">new clinical trial agreement</a>.</li>



<li>Adlai Nortye (NASDAQ:<a href="https://investorplace.com/stock-quotes/anl-stock-quote/">ANL</a>) shares are up nearly 16% on Tuesday.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Lufax (NYSE:<a href="https://investorplace.com/stock-quotes/lu-stock-quote/">LU</a>) stock is plummeting more than 51% without any apparent news from the company.</li>



<li>Hywin (NASDAQ:<a href="https://investorplace.com/stock-quotes/hyw-stock-quote/">HYW</a>) shares are diving over 24% after a massive rally on Monday.</li>



<li>Avalon Globocare (NASDAQ:<a href="https://investorplace.com/stock-quotes/albt-stock-quote/">ALBT</a>) stock is tumbling more than 20% after a major rally yesterday.</li>



<li>Binah Capital (NASDAQ:<a href="https://investorplace.com/stock-quotes/bcg-stock-quote/">BCG</a>) shares are taking an over 17% beating without any news to report today.</li>



<li>CalAmp (NASDAQ:<a href="https://investorplace.com/stock-quotes/camp-stock-quote/">CAMP</a>) stock is sliding more than 15% following <a href="https://finance.yahoo.com/news/calamp-reaches-comprehensive-agreement-significantly-132500316.html">a bankruptcy filing</a>.</li>



<li>Sequans Communications (NYSE:<a href="https://investorplace.com/stock-quotes/sqns-stock-quote/">SQNS</a>) shares are dropping over 14% on Tuesday morning.</li>



<li>Direxion Daily MSCI India Bull 2X Shares (NYSEARCA:<a href="https://investorplace.com/stock-quotes/indl-stock-quote/">INDL</a>) are falling more than 14% this morning.</li>



<li>MingZhu Logistics (NASDAQ:<a href="https://investorplace.com/stock-quotes/ygmz-stock-quote/">YGMZ</a>) stock is slipping over 14% after a rally yesterday.</li>



<li>Primech (NASDAQ:<a href="https://investorplace.com/stock-quotes/pmec-stock-quote/">PMEC</a>) shares are dipping 14% after jumping yesterday.</li>



<li>A2Z Smart Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/az-stock-quote/">AZ</a>) stock closes out our pre-market stock movers down over 12%.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/06/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-tuesday-june-4th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

Primech Holdings Ltd. (PMEC) has released an update. Primech Holdings Ltd. has entered into a six-month consulting agreement with Jolly Good River ...

Primech Holdings Strengthens Strategy with New Consulting Pact

Primech Holdings reports FY results

Primech Holdings Ltd. (PMEC) has released an update. Primech Holdings Ltd. is set to hold its Annual General Meeting (AGM) on August 19, 2024, wher...

Primech Holdings AGM Scheduled for Shareholder Decisions

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
It&rsquo;s time to dive into the biggest pre-market stock movers for Wednesday as we check out all of the hottest news happening this morning!



Moving stocks this morning are clinical trial updates, earnings reports and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Primech (NASDAQ:<a href="https://investorplace.com/stock-quotes/pmec-stock-quote/">PMEC</a>) stock is rocketing close to 90% alongside heavy pre-market trading.</li>



<li>Nuzee (NASDAQ:<a href="https://investorplace.com/stock-quotes/nuze-stock-quote/">NUZE</a>) shares are soaring more than 69% with strong early morning trading.</li>



<li>Heramba Electric (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PITA#NASDAQ">PITA</a>) stock is surging over 43% with increasing trading activity this morning.</li>



<li>Bionomics (NASDAQ:<a href="https://investorplace.com/stock-quotes/bnox-stock-quote/">BNOX</a>) shares are gaining more than 31% on a <a href="https://www.nasdaq.com/press-release/bionomics-announces-successful-end-phase-2-meeting-fda-development-bnc210-post">Phase 2 clinical trial meeting</a>.</li>



<li>Powell Industries (NASDAQ:<a href="https://investorplace.com/stock-quotes/powl-stock-quote/">POWL</a>) stock is rising over 25% after <a href="https://finance.yahoo.com/news/powell-industries-powl-q3-earnings-214005995.html">beating Q3 estimates</a>.</li>



<li>BIMI International Medical (NASDAQ:<a href="https://investorplace.com/stock-quotes/bimi-stock-quote/">BIMI</a>) shares are increasing more than 20% with strong early morning trading today.</li>



<li>DallasNews (NASDAQ:<a href="https://investorplace.com/stock-quotes/daln-stock-quote/">DALN</a>) stock is climbing over 18% with its <a href="https://investorplace.com/earning-results/2024/07/daln-stock-earnings-dallasnews-for-q2-of-2024/">Q2 earnings report</a>.</li>



<li>Faraday Future (NASDAQ:<a href="https://investorplace.com/stock-quotes/ffie-stock-quote/">FFIE</a>) shares are jumping more than 17% after <a href="https://finance.yahoo.com/news/faraday-future-regains-compliance-nasdaq-031500213.html">regaining listing compliance</a>.</li>



<li>GraniteShares 2x Long AMD Daily ETF (NASDAQ:<a href="https://investorplace.com/stock-quotes/amdl-stock-quote/">AMDL</a>) stock is getting an over 17% boost this morning.</li>



<li>Talen Energy (NASDAQ:<a href="https://investorplace.com/stock-quotes/tln-stock-quote/">TLN</a>) shares are up more than 17% after <a href="https://www.nasdaq.com/press-release/talen-reports-pjm-auction-results-2025-2026-planning-year-2024-07-30">reporting PJM Auction Results</a>.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>FibroGen (NASDAQ:<a href="https://investorplace.com/stock-quotes/fgen-stock-quote/">FGEN</a>) stock is plummeting over 44% on a <a href="https://www.nasdaq.com/press-release/fibrogen-announces-topline-results-two-late-stage-pamrevlumab-pancreatic-cancer">failed clinical trial</a>.</li>



<li>Macrogenics (NASDAQ:<a href="https://investorplace.com/stock-quotes/mgnx-stock-quote/">MGNX</a>) shares are diving more than 26% as it <a href="https://www.nasdaq.com/press-release/macrogenics-provides-vobramitamab-duocarmazine-update-2024-07-30">discontinues a clinical trial</a>.</li>



<li>Jet AI (NASDAQ:<a href="https://investorplace.com/stock-quotes/jtai-stock-quote/">JTAI</a>) stock is tumbling over 21% on an <a href="https://www.nasdaq.com/press-release/jetai-announces-expiration-and-successful-results-exchange-offer-and-consent">exchange offer for its warrants</a>.</li>



<li>Penumbra (NYSE:<a href="https://investorplace.com/stock-quotes/pen-stock-quote/">PEN</a>) shares are taking a more than 18% beating <a href="https://finance.yahoo.com/news/penumbra-pen-reports-q2-earnings-230019255.html">with its Q2 earnings report</a>.</li>



<li>Groupon (NASDAQ:<a href="https://investorplace.com/stock-quotes/grpn-stock-quote/">GRPN</a>) stock is sliding over 17% <a href="https://investorplace.com/earning-results/2024/07/grpn-stock-earnings-groupon-for-q2-of-2024/">on an EPS miss</a>.</li>



<li>Definitive Healthcare (NASDAQ:<a href="https://investorplace.com/stock-quotes/dh-stock-quote/">DH</a>) shares are falling more than 16% without any clear news this morning.</li>



<li>Netcapital (NASDAQ:<a href="https://investorplace.com/stock-quotes/ncpl-stock-quote/">NCPL</a>) stock is dropping over 16% after <a href="https://investorplace.com/earning-results/2024/07/ncpl-stock-earnings-netcapital-for-q4-of-2024/">missing estimates in fiscal 2024</a>.</li>



<li>O-I Glass (NYSE:<a href="https://investorplace.com/stock-quotes/oi-stock-quote/">OI</a>) shares are decreasing more than 15% <a href="https://www.stocktitan.net/news/OI/o-i-glass-reports-second-quarter-2024-71rm58wp8yg0.html">with its Q2 results</a>.</li>



<li>Lemonade (NYSE:<a href="https://investorplace.com/stock-quotes/lmnd-stock-quote/">LMND</a>) stock is slipping over 13% <a href="https://www.marketwatch.com/story/lemonades-stock-slides-14-after-posting-q2-loss-5e14bea8">alongside a weak guidance</a>.</li>



<li>Tivic Health Systems (NASDAQ:<a href="https://investorplace.com/stock-quotes/tivc-stock-quote/">TIVC</a>) shares close out our pre-market stock movers down 13% <a href="https://investorplace.com/2024/07/tivic-health-systems-tivc-stock-pops-another-39-july-29th/">after a rally yesterday</a>.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/07/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-wednesday-july-31st/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Primech&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/pmec-stock-quote/">PMEC</a>) stock is rocketing higher on Wednesday alongside heavy pre-market trading of the facilities and stewarding services company&rsquo;s shares.



This has more than 7.6 million shares changing hands as of this writing. That&rsquo;s already well above its daily average trading volume of about 239,000 shares. Investors will also note that Primech&rsquo;s float is <a href="https://finance.yahoo.com/quote/PMEC/key-statistics/">only about 6.76 million units</a>.



There are no updates from PMEC that explain why the company&rsquo;s stock is up today. That includes a lack of press releases or filings with the Securities and Exchange Commission (SEC). There also isn&rsquo;t any analyst coverage that would cause today&rsquo;s rally.



What is worth keeping in mind is PMEC being a penny stock. That comes from its prior closing price of 53 cents and a market capitalization of only $20.022 million.



<h2>What That Means for PMEC Stock</h2>



Being a penny stock comes with certain concerns that traders should keep in mind. That includes extra volatility alongside heavy trading of the company&rsquo;s stock.



Primech shares could be rallying today due to manipulation from retail and day traders. It could also be up as speculative traders buy its shares. No matter the case, its a risky investment to take today.



PMEC stock is up 59.7% as of Wednesday morning.



Investors will want to stick around for more of the most recent stock market news today!



We have all of the hottest stock market happenings worth reading about on Wednesday! That includes the biggest pre-market stock movers and other news. You can catch up on all of this by checking out the links below!



<h2>More Wednesday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2024/07/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-wednesday-july-31st/">Today&rsquo;s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on&nbsp;Wednesday</a></li>



<li><a href="https://investorplace.com/2024/07/siggraph-2024-what-to-watch-for-nvidia-so-far/">SIGGRAPH 2024: What to Watch for Nvidia So Far</a></li>



<li><a href="https://investorplace.com/2024/07/should-you-buy-intel-intc-stock-before-aug-1/">Should You Buy Intel (INTC) Stock Before Aug. 1?</a></li>
</ul>On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/07/why-is-primech-pmec-stock-up-60-today/">Why Is Primech (PMEC) Stock Up 60% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Primech (PMEC) Stock Up 60% Today?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Nuzee&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/nuze-stock-quote/">NUZE</a>)&nbsp;stock is up on Wednesday with heavy pre-market trading of the coffee&nbsp;and tea company&rsquo;s shares this morning.



That has more than 4 million shares of NUZE stock on the move as of this writing. This is already above its daily average trading volume of about 3 million shares. It&rsquo;s also worth noting that the company&rsquo;s <a href="https://finance.yahoo.com/quote/NUZE/key-statistics/">float is roughly 406,140 units</a>.



This movement comes without any clear news from Nuzee. The single-serve coffee company hasn&rsquo;t released any press releases or filings that would cause this morning&rsquo;s rally. There&rsquo;s also no analyst coverage that would act as a catalyst for today&rsquo;s movement.



Instead, traders will keep in mind that NUZE is a penny stock. That comes from its prior closing price of $3.70 per share and a market capitalization of just $16.385 million.



<h2>How This Affects NUZE Stock</h2>



Being a penny stock opens Nuzee up to certain vulnerabilities. That includes volatility alongside the strong trading of its shares.



This could be the sign of manipulation by retail or day traders. If that&rsquo;s the case, it makes NUZE stock a risky investment this morning as the pump likely won&rsquo;t last long before the dump. It could also be a sign of speculative traders buying its shares.



NUZE stock is up 64.3% as of Wednesday morning.



There are more stock market stories traders will want to read about below!



We have all of the hottest stock market news ready to go on Wednesday! Among that is what has shares of Primech&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/pmec-stock-quote/">PMEC</a>) stock up, the biggest pre-market stock movers this morning and more. All of this info is ready to go at the links below!



<h2>More Wednesday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2024/07/why-is-primech-pmec-stock-up-60-today/">Why Is Primech (PMEC) Stock Up 60% Today?</a></li>



<li><a href="https://investorplace.com/2024/07/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-wednesday-july-31st/">Today&rsquo;s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on&nbsp;Wednesday</a></li>



<li><a href="https://investorplace.com/2024/07/siggraph-2024-what-to-watch-for-nvidia-so-far/">SIGGRAPH 2024: What to Watch for Nvidia So Far</a></li>
</ul>On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/07/why-is-nuzee-nuze-stock-up-64-today/">Why Is Nuzee (NUZE) Stock Up 64% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Nuzee (NUZE) Stock Up 64% Today?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Macrogenics&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/mgnx-stock-quote/">MGNX</a>) stock is dropping on Wednesday as the biopharmaceutical company prepares to <a href="https://www.nasdaq.com/press-release/macrogenics-provides-vobramitamab-duocarmazine-update-2024-07-30">discontinue a clinical trial</a> of vobramitamab duocarmazine.



This is the company&rsquo;s candidate for metastatic castration-resistant prostate cancer (mCRPC). The company has decided to no longer move forward with its TAMARACK Phase 2 study for patients who could have received additional doses.



Macrogenics&nbsp;is making this decision due to the primary endpoint of its study already being met. This suggestion came from the Independent Data Monitoring Committee (IDMC) of the clinical trial. It will present this data in a poster presentation in September.



Scott Koenig, M.D., Ph.D., president and CEO of&nbsp;MacroGenics, said the following about the news.




&ldquo;Patient safety is our top priority, and having reached the study&rsquo;s primary endpoint, we decided to discontinue additional dosing for the remaining TAMARACK participants who had not yet completed treatment. We expect to have the data necessary to determine next steps for the vobra duo program later this year and will provide further updates on an investor call following our ESMO presentation.&rdquo;




<h2>How This Affects MGNX Stock</h2>



Investors aren&rsquo;t reacting well to this news with shares of MGNX stock falling 28.2% as of Wednesday morning. The stock was also down 48.3% year-to-date when markets closed on Tuesday.



Investors who are seeking out even more of the most recent stock market stories today are in the right place!



We have all of the hottest stock market happenings that traders need to read about on Wednesday! That includes everything happening with shares of FibroGen&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/fgen-stock-quote/">FGEN</a>) stock, Nuzee&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/nuze-stock-quote/">NUZE</a>) stock and Primech&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/pmec-stock-quote/">PMEC</a>) stock this morning. You can catch up on all of these matters by checking out the links below!



<h2>More Stock Market News for Wednesday</h2>



<ul><li><a href="https://investorplace.com/2024/07/why-is-fibrogen-fgen-stock-down-44-today/">Why Is FibroGen (FGEN) Stock Down 44% Today?</a></li>



<li><a href="https://investorplace.com/2024/07/why-is-nuzee-nuze-stock-up-64-today/">Why Is Nuzee (NUZE) Stock Up 64% Today?</a></li>



<li><a href="https://investorplace.com/2024/07/why-is-primech-pmec-stock-up-60-today/">Why Is Primech (PMEC) Stock Up 60% Today?</a></li>
</ul>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/07/why-is-macrogenics-mgnx-stock-down-28-today/">Why is Macrogenics (MGNX) Stock Down 28% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why is Macrogenics (MGNX) Stock Down 28% Today?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
FibroGen&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/fgen-stock-quote/">FGEN</a>) stock is falling hard on Wednesday after the biopharmaceutical company <a href="https://www.nasdaq.com/press-release/fibrogen-announces-topline-results-two-late-stage-pamrevlumab-pancreatic-cancer">reported results from failed clinical trials</a>.



The first failed clinical trial covers the treatment of metastatic pancreatic cancer with pamrevlumab. FibroGen&nbsp;said that this didn&rsquo;t meet its primary endpoint of overall survival. This was determined based on the protocol pre-specified Bayesian statistical analysis.



The second failed study covered the use of pamrevlumab&nbsp;combined with gemcitabine + nab-paclitaxel to treat unresectable pancreatic cancer. Yet again, the clinical trial failed to reach its primary endpoint of overall survival.



These are major blows to FibroGen&nbsp;as these weren&rsquo;t early clinical trials. The metastatic pancreatic cancer trial was in the Phase 2/3 range while the unresectable pancreatic cancer one was a Phase 3 study.



FibroGen&nbsp;CEO Thane Wettig said the following about the clinical trial results.




&ldquo;We are deeply disappointed that the pamrevlumab arm in the Precision Promise trial and the LAPIS trial did not meet the primary endpoint of overall survival. We were hopeful that pamrevlumab could bring meaningful innovation to pancreatic cancer patients in desperate need of new therapies.&rdquo;




<h2>What&rsquo;s Next for FGEN Stock</h2>



Considering the results of these clinical trials, FibroGen&nbsp;is immediately going to go into cost-saving mode. That includes the termination of the pamrevlumab program. This will reduce its total headcount by 75%.



FGEN stock is down 44.4% as of Wednesday morning.



Investors will want to stick around for more of the most recent stock market news!



We have all of the latest market happenings worth reading about today! A few examples include what&rsquo;s going on with shares of Nuzee&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/nuze-stock-quote/">NUZE</a>) and Primech&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/pmec-stock-quote/">PMEC</a>) stock, as well as the biggest pre-market stock movers this morning. All of this info is ready to go at the links below!



<h2>More Wednesday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2024/07/why-is-nuzee-nuze-stock-up-64-today/">Why Is Nuzee (NUZE) Stock Up 64% Today?</a></li>



<li><a href="https://investorplace.com/2024/07/why-is-primech-pmec-stock-up-60-today/">Why Is Primech (PMEC) Stock Up 60% Today?</a></li>



<li><a href="https://investorplace.com/2024/07/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-wednesday-july-31st/">Today&rsquo;s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on&nbsp;Wednesday</a></li>
</ul>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/07/why-is-fibrogen-fgen-stock-down-44-today/">Why Is FibroGen (FGEN) Stock Down 44% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is FibroGen (FGEN) Stock Down 44% Today?

Primech Holdings Ltd. (PMEC) has released an update. At Primech Holdings Ltd.'s 2024 Annual Meeting, shareholders overwhelmingly approved the Direc...

Primech Holdings Shareholders Approve Key Resolutions

ALBT

AMDL

ANNX

BIMI

BNOX

CAMP

CORZ

DALN

DTSS

FFIE

FGEN

FRES

GRPN

INDL

JTAI

LEXX

LMND

MGNX

MLGO

NCPL

NUZE

PITA

PLTN

PMEC

POWL

SQNS

TIVC

WIMI

YGMZ

Press Releases

PRIMECH HOLDINGS LTD. Announces Pricing of US12.2 Million Initial Public Offering

Primech Holdings Limited Provides Financial Updates and Corporate Highlights For the Six Months Ended September 30, 2023

Contracts

Primech Holdings Limited Engages Strategic Investor Relations to Enhance Investor Communications and Engagement

Primech Holdings Limited Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

Primech Holdings Launches Primech Ai, the Creator of a Fully Autonomous, Ai-Powered Toilet-Cleaning Robot

Primech Holdings Reports 5.1% Increase in Revenue, $144.4 Million in Future Contracted Revenues Guidance

Primech Holdings Subsidiary Nominated as a Finalist for the Singapore Apex Corporate Sustainability Awards

Comments

Primech Holdings

Interés en corto

Primech Holdings (NASDAQ:PMEC) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL